Ulf Schnetzke

GLA/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany

Wolfgang Bethge, Peter Martus, Michael Schmitt et al. · Blood · 2022 · 211 citations · Full text

Medicine, Hematology, Oncology +15

Cell transformation by FLT3 ITD in acute myeloid leukemia involves oxidative inactivation of the tumor suppressor protein-tyrosine phosphatase DEP-1/ PTPRJ

Rinesh Godfrey, Deepika Arora, Reinhard Bauer et al. · Blood · 2012 · 79 citations · Full text

Medicine, Cell Biology, Oncology +16

Ponatinib may overcome resistance of <scp>FLT</scp>3‐<scp>ITD</scp> harbouring additional point mutations, notably the previously refractory <scp>F</scp>691I mutation

Elisabeth Zirm, Bärbel Spies‐Weisshart, Florian H. Heidel et al. · British Journal of Haematology · 2012 · 51 citations

Medicine, Molecular Medicine, Oncology +16

In Vivo Emergence of UL56 C325Y Cytomegalovirus Resistance to Letermovir in a Patient with Acute Myeloid Leukemia after Hematopoietic Cell Transplantation

Jochen J. Frietsch, Detlef Michel, Thomas Stamminger et al. · Mediterranean Journal of Hematology and Infectious Diseases · 2019 · 50 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Polymorphisms of Toll-like receptors (TLR2 and TLR4) are associated with the risk of infectious complications in acute myeloid leukemia

Ulf Schnetzke, Bärbel Spies‐Weisshart, Olaposi Yomade et al. · Genes and Immunity · 2014 · 48 citations

Life Sciences, Immunology, Infectious Diseases +16